Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails

Bristol Myers Squibb Stock Rockets — And AbbVie Stock Dives

Bristol Myers Squibb (BMY) stock rocketed Monday after AbbVie's (ABBV) experimental schizophrenia treatment failed in a pair of midstage studies ...

AbbVie's stock plummets over 12% after schizophrenia drug flops in ...

The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS.

Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

Bristol Myers Rockets 12% On AbbVie's Schizophrenia Failure

It's the first drug in its class. AbbVie was looking to rival Cobenfy with its drug, emraclidine. But emraclidine failed to make a difference in ...

AbbVie's $9B schizophrenia prospect flunks phase 2 trials

The drug candidate at the center of AbbVie's $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, ...

Investors.com on X: "Bristol Myers Rockets After AbbVie's ...

Bristol Myers Rockets After AbbVie's Schizophrenia Drug Fails https://t.co/BHbBistRqM.

AbbVie's closely watched schizophrenia drug fails two ... - Reuters

AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ... Bristol Myers Squibb's lead in the market for new treatments ...

AbbVie's $9B bet collapses as closely watched schizophrenia drug ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn't best placebo in two Phase 2 trials.

On Wall Street, 'flat out' failure of AbbVie schizophrenia drug leaves ...

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in ...

AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint

Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

Bristol Myers Rockets 12% On AbbVie's Schizophrenia Failure

Bristol Myers Rockets After AbbVie's Schizophrenia Drug Fails https://lnkd.in/grb8iiim.

Advantage BMS as AbbVie drug fails schizophrenia trials

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 ...

Allison Gatlin on X: "$BMY rocketed after $ABBV's schizophrenia ...

BMY rocketed after $ABBV's schizophrenia drug, emraclidine failed ... Bristol Myers Rockets 12% On AbbVie's Schizophrenia Failure · From ...

Bristol Rockets 11% As Investors Question AbbVie's… - Inkl

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

AbbVie's disappointing schizophrenia drug trial bodes well for rival ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

AbbVie Stock Tumbles on Failed Schizophrenia Drug ... - Barron's

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. ... Shares of AbbVie were getting hammered Monday after the drug ...

AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails ...

The shocking failure of AbbVie's emraclidine has investors questioning the Big Pharma's long-term neuroscience strategy, which put the drug at ...

ABBV - Abbvie Inc Stock Price and Quote - FINVIZ.com

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. (Barrons.com). 10:12AM · Bristol Myers Rockets 12% After AbbVie's ...

Azurity Wins FDA Approval for Oral CML Drug - BioSpace

BMS made recent history on Thursday with the approval of Cobenfy—formerly KarXT—as the first novel therapeutic for schizophrenia in 35 years. While treatment ...

ARS Pharmaceuticals Scores $145 Million Deal For Nasal Spray

ARS Pharmaceuticals shares jumped Monday after the company inked a ... Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails.